Research library

A

grade

GLP-1 receptor agonists may reduce cardiovascular and kidney-related events in patients with chronic kidney disease, but further investigation is needed to confirm these findings and assess long-term effects.

16% reduction in MACE (HR 0.84, 95% CI 0.79-0.89; high certainty)

summary

A

grade

GLP-1 receptor agonists reduce major adverse cardiovascular events similarly in patients with different kidney functions, with a greater absolute benefit seen in those with lower kidney function.

Pooled HR for MACE with eGFR ≥ 60 mL/min/1.73 m² was 0.83 (95% CI 0.77-0.90; p < 0.001; I² = 35.6%)

summary

B

grade

Only 6.2% of Medicare beneficiaries with Part D are using GLP-1 RAs, highlighting a gap between eligibility and actual treatment uptake.

6.2% of Medicare FFS beneficiaries with Part D (n=16,474,786) had GLP-1 RAs.

summary

B

grade

Tirzepatide treatment was associated with a significant reduction in body weight and insulin requirements in adults with Type 1 diabetes and obesity, but further studies are needed to confirm these findings.

-10.01% ± 4.74% body weight reduction vs +0.69% ± 3.77% in controls, adj-p < 0.0001

summary

B

grade

GLP-1 therapy may be associated with a reduced risk of venous complications and improved survival in obese patients with chronic venous insufficiency.

HR for acute DVT risk at 1 year was 0.54; 95% CI, 0.42-0.71; P < .001.

summary

B

grade

GLP-1RA therapy is associated with a higher risk of laryngeal symptoms, particularly cough and voice disorders, although the absolute risk increases are small.

GLP-1RA therapy increased the 6-month risk of any laryngeal manifestations (OR 1.19, 95% CI 1.16-1.21; p<0.0001).

summary

A

grade

Ecnoglutide does not significantly affect the pharmacokinetics of rosuvastatin or digoxin, so no dose adjustments are necessary when these drugs are co-administered.

Geometric mean ratio for rosuvastatin with ecnoglutide was 106% (94%, 120%)

summary

B

grade

Semaglutide shows a higher potential for misuse compared to other GLP-1 receptor agonists based on adverse event reports, but further research is needed to confirm these findings.

PRR for 'drug abuse' for semaglutide was 4.05 (p<0.01).

summary

B

grade

The study suggests that using a precision medicine approach can help identify which type 2 diabetes patients will benefit most from specific glucose-lowering therapies.

≥5 mmol/mol HbA1c benefits associated with each drug class.

summary

B

grade

Semaglutide shows a higher potential for misuse compared to other GLP-1 receptor agonists, with significant reporting ratios for various misuse-related adverse events.

PRR for 'drug abuse' with semaglutide was 4.05 (p<0.01).

summary

A

grade

SGLT2 inhibitors are effective in lowering HbA1c and reducing cardiovascular risks, with efficacy varying by age, but age alone should not preclude treatment.

SGLT2i reduced HbA1c by 0.5-1.0% overall compared to placebo.

summary

A

grade

Empagliflozin showed a potential lower risk for ventricular arrhythmias, but this finding needs confirmation in future trials. SGLT2 inhibitors consistently reduced hospitalization for heart failure across both networks.

OR 0.31, 95% CI 0.11-0.86 for lower VA risk with empagliflozin in the T2DM network.

summary

A

grade

GLP-1-based therapies, including albiglutide, may be associated with cardiovascular benefits in Type 2 diabetes, but many comparisons for mortality outcomes were not statistically significant.

Not reported in abstract.

summary

A

grade

Semaglutide shows a significant reduction in cardiovascular events, but practitioners should consider the associated gastrointestinal risks and high cost-effectiveness ratios.

32% reduction in major adverse cardiovascular events (MACE) with semaglutide, OR=0.68, 95% CI 0.52-0.91.

summary

D

grade

Not reported in abstract.

summary